THERAVANCE

A Phase 2, randomised, double-blind, placebo-controlled, parallel-group, multi-centre study of an inhaled Pan-Janus Kinase Inhibitor, TD-0903, to treat symptomatic acute lung injury associated with COVID-19.

Type: Interventional

Site and lead:

  • Wythenshawe Hospital: Dr Rob Lord

Patient group: COVID-19 patients requiring supplemental oxygen

Intervention:

  • Pan-Janus Kinase Inhibitor (TD-0903)